Open main menu


Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Telura, is a fixed dose combination medication for the treatment of HIV/AIDS.[1] It combines efavirenz, lamivudine, and tenofovir.[1] As of 2019 it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir.[2] It is taken by mouth.[1]

Combination of
EfavirenzNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
TenofovirNucleoside reverse transcriptase inhibitor
Clinical data
Trade namesTelura
Routes of
By mouth
ATC code

Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness.[1] Severe side effects may include depression, psychosis, or osteonecrosis.[1] In those with a history of epilepsy, it may increase the frequency of seizures.[1] Greater care should also be taken in those with kidney problems.[1] It is unclear if use during pregnancy is safe.[1][3]

The combination is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[4] A year of medication is estimated to costs 154 USD in the developing world as of 2011.[1] The combination received tentative approval in the United States in 2014.[5] Its availability and importance is supported by Medecins Sans Frontieres.[6]


  1. ^ a b c d e f g h i "WHO Model List of Essential Medicines Application" (PDF). WHO. Retrieved 29 June 2017.
  2. ^ "UPDATE OF RECOMMENDATIONS ON FIRST- AND SECOND-LINE ANTIRETROVIRAL REGIMENS" (PDF). World Health Organization. July 2019. Retrieved 16 November 2019.
  3. ^ "Telura" (PDF). 2014. Retrieved 13 December 2017.
  4. ^ "WHO Model List of Essential Medicines (20th List)" (PDF). World Health Organization. March 2017. Retrieved 29 June 2017.
  5. ^ "HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line 2010 - 2015". FDA. Retrieved 13 December 2017.
  6. ^ "Efavirenz/lamivudine/tenofovir disoproxil fumarate fixed-dose combination tablets (600/300/300 mg FDC)" (PDF). WHO. p. 17.